What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
The sale represented 23.29% of Zante's direct holdings, which fell from 247,552 to 189,891 shares, as reported. All activity occurred in direct ownership -- no indirect entities or family trusts were involved; the transaction included derivative context. These 10 stocks could mint the next wave of millionaires › Greg Zante, the chief financial officer of Viking Therapeutics (NASDAQ:VKTX) , reported the direct sale of 57,661 shares of the biotech in multiple open-market transactions valued at $1.9 million, according to a recent SEC Form 4 filing Metric Value Shares sold (direct) Transaction value $1.9 million Post-transaction shares (direct) Post-transaction value (direct ownership) $6.1 million Transaction value based on SEC Form 4 weighted average purchase price ($32.90); post-transaction value based on position value at the Monday transaction price. How significant was this sale relative to Greg Zante's recent trading activity? This 57,661-share disposit
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPR Newswire
- Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? [Yahoo! Finance]Yahoo! Finance
- VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug [Yahoo! Finance]Yahoo! Finance
- Lightning Round: QXO is a buy, says Jim Cramer [CNBC]CNBC
- Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- VKTX's page on the SEC website